Upadacitinib Global Patent Coverage & Expiry Overview

Track protection status across key markets to assess launch feasibility.

It is formulated by 1 pharmaceutical company such as ABBVIE. It is marketed under 2 brand names, including RINVOQ, RINVOQ LQ. Available in 4 different strengths, such as 15MG, 30MG, 45MG and others, and administered through 2 routes including TABLET, EXTENDED RELEASE;ORAL, SOLUTION;ORAL.

Strategic Dashboard

info

insightsStrategic Insights

Sourcing & Feasibility

check_circle API availability: autorenew Loading API feasibility...

groups Licensing: 1 potential partners

calendar_todayUS Launch window: autorenew Loading launch window...

timeline Key Patent Barrier & Expiry Timeline

autorenew Loading patent barriers...

factoryGeneric Manufacturer Snapshot

autorenew Loading manufacturers...

gavelRisk & Opportunity Summary

dangerous Risk: autorenew Loading risk analysis...

watch_later Watch: autorenew Loading watch analysis...

rocket_launch Opportunity: autorenew Loading opportunity analysis...

Country

flag

Legal Status

gavel

Expiry From

calendar_today

Expiry To

calendar_today

Access Global Patent Data

Stay ahead with worldwide patent expiry and latest updates.

✓ Comprehensive global patent expiry timelines

✓ Full patent family details and status updates

Unlock Global Patents

Orange Book Drug Approval Timeline

FDA approval history for this ingredient

NDA (New Drug Application) ANDA (Generic Application)

Access Global Exclusivity and Patent Expiry Extensions

Stay ahead with worldwide patent expiry insights, exclusivity data, and latest updates.

✓ Comprehensive global patent expiry timelines

✓ Full patent family details and status updates

✓ Latest exclusivity data and extensions

Unlock Global Access

US Orange Book Patents Expiration Timeline

Key expiration dates for US patents covering this ingredient

View Global Patents Expiration Timeline

Stay ahead with worldwide patent expiry insights, market data, and research updates.

✓ Comprehensive global patent expiry timelines

✓ Full patent family details and status updates

Unlock Global Patent Timeline

Orange Book Drug Strengths

Latest drug strengths approved by FDA

Strength	Route of Administration	Companies	Latest Approval Date

Orange Book Patents

Patents approved by the FDA for the ingredient

	Patent Number	Publication Date	Legal Status	Patent Expiry Date
{"application_id":"35388","ingredient":"UPADACITINIB","trade_name":"RINVOQ","family_id":"c10de62e31b54e5fbe6b","publication_number":"US8962629B2","cleaned_patent_number":"8962629","drug_product_flag":"-","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2031-01-15","publication_date":"2015-02-24","legal_status":"Granted"}	US8962629B2 Molecular	24 Feb, 2015	Granted	15 Jan, 2031
{"application_id":"22560","ingredient":"UPADACITINIB","trade_name":"RINVOQ","family_id":"c10de62e31b54e5fbe6b","publication_number":"USRE47221E","cleaned_patent_number":"RE47221","drug_product_flag":"-","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2033-08-16","publication_date":"2019-02-05","legal_status":"Granted"}	USRE47221E1 Molecular	05 Feb, 2019	Granted	16 Aug, 2033
{"application_id":"34356","ingredient":"UPADACITINIB","trade_name":"RINVOQ","family_id":"c377044a6f994b4a802a","publication_number":"US10519164B2","cleaned_patent_number":"10519164","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2036-10-17","publication_date":"2019-12-31","legal_status":"Patented case"}	US10519164B2 Formulation	31 Dec, 2019	Patented case	17 Oct, 2036
{"application_id":"34348","ingredient":"UPADACITINIB","trade_name":"RINVOQ","family_id":"c377044a6f994b4a802a","publication_number":"US10550126B2","cleaned_patent_number":"10550126","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2036-10-17","publication_date":"2020-02-04","legal_status":"Patented case"}	US10550126B2	04 Feb, 2020	Patented case	17 Oct, 2036
{"application_id":"34357","ingredient":"UPADACITINIB","trade_name":"RINVOQ","family_id":"c377044a6f994b4a802a","publication_number":"US10597400B2","cleaned_patent_number":"10597400","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2036-10-17","publication_date":"2020-03-24","legal_status":"Granted"}	US10597400B2	24 Mar, 2020	Granted	17 Oct, 2036
{"application_id":"34359","ingredient":"UPADACITINIB","trade_name":"RINVOQ","family_id":"c377044a6f994b4a802a","publication_number":"US10730883B2","cleaned_patent_number":"10730883","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2036-10-17","publication_date":"2020-08-04","legal_status":"Granted"}	US10730883B2 Formulation	04 Aug, 2020	Granted	17 Oct, 2036
{"application_id":"34360","ingredient":"UPADACITINIB","trade_name":"RINVOQ","family_id":"c377044a6f994b4a802a","publication_number":"US10981923B2","cleaned_patent_number":"10981923","drug_product_flag":"-","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2036-10-17","publication_date":"2021-04-20","legal_status":"Granted"}	US10981923B2 Molecular	20 Apr, 2021	Granted	17 Oct, 2036
{"application_id":"34361","ingredient":"UPADACITINIB","trade_name":"RINVOQ","family_id":"c377044a6f994b4a802a","publication_number":"US10981924B2","cleaned_patent_number":"10981924","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2036-10-17","publication_date":"2021-04-20","legal_status":"Granted"}	US10981924B2 Formulation	20 Apr, 2021	Granted	17 Oct, 2036
{"application_id":"34347","ingredient":"UPADACITINIB","trade_name":"RINVOQ","family_id":"c377044a6f994b4a802a","publication_number":"US10995095B2","cleaned_patent_number":"10995095","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2036-10-17","publication_date":"2021-05-04","legal_status":"Patented case"}	US10995095B2	04 May, 2021	Patented case	17 Oct, 2036
{"application_id":"34362","ingredient":"UPADACITINIB","trade_name":"RINVOQ","family_id":"c377044a6f994b4a802a","publication_number":"US11186584B2","cleaned_patent_number":"11186584","drug_product_flag":"-","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2036-10-17","publication_date":"2021-11-30","legal_status":"Granted"}	US11186584B2 Molecular	30 Nov, 2021	Granted	17 Oct, 2036
{"application_id":"34364","ingredient":"UPADACITINIB","trade_name":"RINVOQ","family_id":"c377044a6f994b4a802a","publication_number":"US11198697B1","cleaned_patent_number":"11198697","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2036-10-17","publication_date":"2021-12-14","legal_status":"Patented case"}	US11198697B2 Formulation	14 Dec, 2021	Patented case	17 Oct, 2036
{"application_id":"34365","ingredient":"UPADACITINIB","trade_name":"RINVOQ","family_id":"c377044a6f994b4a802a","publication_number":"US11365198B2","cleaned_patent_number":"11365198","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2036-10-17","publication_date":"2022-06-21","legal_status":"Granted"}	US11365198B2	21 Jun, 2022	Granted	17 Oct, 2036
{"application_id":"104821","ingredient":"UPADACITINIB","trade_name":"RINVOQ","family_id":"c377044a6f994b4a802a","publication_number":"US11512092B2","cleaned_patent_number":"11512092","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2036-10-17","publication_date":"2022-11-29","legal_status":"Granted"}	US11512092B2	29 Nov, 2022	Granted	17 Oct, 2036
{"application_id":"104664","ingredient":"UPADACITINIB","trade_name":"RINVOQ","family_id":"c377044a6f994b4a802a","publication_number":"US11524964B2","cleaned_patent_number":"11524964","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2036-10-17","publication_date":"2022-12-13","legal_status":"Patented case"}	US11524964B2	13 Dec, 2022	Patented case	17 Oct, 2036
{"application_id":"106737","ingredient":"UPADACITINIB","trade_name":"RINVOQ","family_id":"c377044a6f994b4a802a","publication_number":"US11535624B2","cleaned_patent_number":"11535624","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2036-10-17","publication_date":"2022-12-27","legal_status":"Granted"}	US11535624B2	27 Dec, 2022	Granted	17 Oct, 2036
{"application_id":"107416","ingredient":"UPADACITINIB","trade_name":"RINVOQ","family_id":"c377044a6f994b4a802a","publication_number":"US11535625B2","cleaned_patent_number":"11535625","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2036-10-17","publication_date":"2022-12-27","legal_status":"Granted"}	US11535625B2	27 Dec, 2022	Granted	17 Oct, 2036
{"application_id":"108188","ingredient":"UPADACITINIB","trade_name":"RINVOQ","family_id":"c377044a6f994b4a802a","publication_number":"US11535626B2","cleaned_patent_number":"11535626","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2036-10-17","publication_date":"2022-12-27","legal_status":"Patented case"}	US11535626B2	27 Dec, 2022	Patented case	17 Oct, 2036
{"application_id":"109608","ingredient":"UPADACITINIB","trade_name":"RINVOQ","family_id":"c377044a6f994b4a802a","publication_number":"US11661425B2","cleaned_patent_number":"11661425","drug_product_flag":"-, Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2036-10-17","publication_date":"2023-05-30","legal_status":"Granted"}	US11661425B2 Molecular	30 May, 2023	Granted	17 Oct, 2036
{"application_id":"109607","ingredient":"UPADACITINIB","trade_name":"RINVOQ","family_id":"c377044a6f994b4a802a","publication_number":"US11680069B2","cleaned_patent_number":"11680069","drug_product_flag":"-, Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2036-10-17","publication_date":"2023-06-20","legal_status":"Patented case"}	US11680069B2 Molecular	20 Jun, 2023	Patented case	17 Oct, 2036
{"application_id":"110390","ingredient":"UPADACITINIB","trade_name":"RINVOQ","family_id":"c377044a6f994b4a802a","publication_number":"US11718627B2","cleaned_patent_number":"11718627","drug_product_flag":"-, Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2036-10-17","publication_date":"2023-08-08","legal_status":"Granted"}	US11718627B2 Molecular	08 Aug, 2023	Granted	17 Oct, 2036
{"application_id":"111203","ingredient":"UPADACITINIB","trade_name":"RINVOQ","family_id":"c377044a6f994b4a802a","publication_number":"US11767326B2","cleaned_patent_number":"11767326","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2036-10-17","publication_date":"2023-09-26","legal_status":"Granted"}	US11767326B2	26 Sep, 2023	Granted	17 Oct, 2036
{"application_id":"110391","ingredient":"UPADACITINIB","trade_name":"RINVOQ","family_id":"c377044a6f994b4a802a","publication_number":"US11773105B2","cleaned_patent_number":"11773105","drug_product_flag":"-, Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2036-10-17","publication_date":"2023-10-03","legal_status":"Granted"}	US11773105B2 Molecular	03 Oct, 2023	Granted	17 Oct, 2036
{"application_id":"111593","ingredient":"UPADACITINIB","trade_name":"RINVOQ","family_id":"c377044a6f994b4a802a","publication_number":"US11773106B2","cleaned_patent_number":"11773106","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2036-10-17","publication_date":"2023-10-03","legal_status":"Granted"}	US11773106B2	03 Oct, 2023	Granted	17 Oct, 2036
{"application_id":"111248","ingredient":"UPADACITINIB","trade_name":"RINVOQ","family_id":"c377044a6f994b4a802a","publication_number":"US11780847B2","cleaned_patent_number":"11780847","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2036-10-17","publication_date":"2023-10-10","legal_status":"Patented case"}	US11780847B2 Formulation	10 Oct, 2023	Patented case	17 Oct, 2036
{"application_id":"111201","ingredient":"UPADACITINIB","trade_name":"RINVOQ","family_id":"c377044a6f994b4a802a","publication_number":"US11780848B2","cleaned_patent_number":"11780848","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2036-10-17","publication_date":"2023-10-10","legal_status":"Granted"}	US11780848B2	10 Oct, 2023	Granted	17 Oct, 2036
{"application_id":"111246","ingredient":"UPADACITINIB","trade_name":"RINVOQ","family_id":"c377044a6f994b4a802a","publication_number":"US11787815B2","cleaned_patent_number":"11787815","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2036-10-17","publication_date":"2023-10-17","legal_status":"Patented case"}	US11787815B2 Formulation	17 Oct, 2023	Patented case	17 Oct, 2036
{"application_id":"113476","ingredient":"UPADACITINIB","trade_name":"RINVOQ","family_id":"c377044a6f994b4a802a","publication_number":"US11795175B2","cleaned_patent_number":"11795175","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2036-10-17","publication_date":"2023-10-24","legal_status":"Granted"}	US11795175B2	24 Oct, 2023	Granted	17 Oct, 2036
{"application_id":"111206","ingredient":"UPADACITINIB","trade_name":"RINVOQ","family_id":"c377044a6f994b4a802a","publication_number":"US11976077B2","cleaned_patent_number":"11976077","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2036-10-17","publication_date":"2024-05-07","legal_status":"Patented case"}	US11976077B2	07 May, 2024	Patented case	17 Oct, 2036
{"application_id":"114630","ingredient":"UPADACITINIB","trade_name":"RINVOQ","family_id":"c377044a6f994b4a802a","publication_number":"US11993605B2","cleaned_patent_number":"11993605","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2036-10-17","publication_date":"2024-05-28","legal_status":"Granted"}	US11993605B2	28 May, 2024	Granted	17 Oct, 2036
{"application_id":"113933","ingredient":"UPADACITINIB","trade_name":"RINVOQ","family_id":"c377044a6f994b4a802a","publication_number":"US11993606B2","cleaned_patent_number":"11993606","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2036-10-17","publication_date":"2024-05-28","legal_status":"Patented case"}	US11993606B2	28 May, 2024	Patented case	17 Oct, 2036
{"application_id":"123370","ingredient":"UPADACITINIB","trade_name":"RINVOQ","family_id":"c377044a6f994b4a802a","publication_number":"US12077545B2","cleaned_patent_number":"12077545","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2036-10-17","publication_date":"2024-09-03","legal_status":"Granted"}	US12077545B2 Formulation	03 Sep, 2024	Granted	17 Oct, 2036
{"application_id":"113062","ingredient":"UPADACITINIB","trade_name":"RINVOQ","family_id":"c377044a6f994b4a802a","publication_number":"","cleaned_patent_number":"12091415","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2036-10-17","publication_date":"2024-09-17","legal_status":"Patented case"}	US12091415B2 Formulation	17 Sep, 2024	Patented case	17 Oct, 2036
{"application_id":"113064","ingredient":"UPADACITINIB","trade_name":"RINVOQ","family_id":"c377044a6f994b4a802a","publication_number":"US20230322794A1","cleaned_patent_number":"12103933","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2036-10-17","publication_date":"2024-10-01","legal_status":"Granted"}	US12103933B2 Formulation	01 Oct, 2024	Granted	17 Oct, 2036
{"application_id":"113063","ingredient":"UPADACITINIB","trade_name":"RINVOQ","family_id":"c377044a6f994b4a802a","publication_number":"US20230348481A1","cleaned_patent_number":"12110297","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2036-10-17","publication_date":"2024-10-08","legal_status":"Granted"}	US12110297B2 Formulation	08 Oct, 2024	Granted	17 Oct, 2036
{"application_id":"114276","ingredient":"UPADACITINIB","trade_name":"RINVOQ","family_id":"c377044a6f994b4a802a","publication_number":"US20240010656A1","cleaned_patent_number":"12110298","drug_product_flag":"-, Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2036-10-17","publication_date":"2024-10-08","legal_status":"Pending"}	US12110298B2 Molecular	08 Oct, 2024	Pending	17 Oct, 2036
{"application_id":"34353","ingredient":"UPADACITINIB","trade_name":"RINVOQ","family_id":"c377044a6f994b4a802a","publication_number":"US10202393B2","cleaned_patent_number":"10202393","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2036-10-17","publication_date":"2019-02-12","legal_status":"Granted"}	US10202393B2 Formulation	12 Feb, 2019	Granted	17 Oct, 2036
{"application_id":"113061","ingredient":"UPADACITINIB","trade_name":"RINVOQ","family_id":"c377044a6f994b4a802a","publication_number":"US20230312595A1","cleaned_patent_number":"12134621","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2036-10-17","publication_date":"2024-11-05","legal_status":"Pending"}	US12134621B2 Formulation	05 Nov, 2024	Pending	17 Oct, 2036
{"application_id":"113060","ingredient":"UPADACITINIB","trade_name":"RINVOQ","family_id":"c377044a6f994b4a802a","publication_number":"US20240034740A1","cleaned_patent_number":"12116373","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2036-10-17","publication_date":"2024-10-15","legal_status":"Granted"}	US12116373B2 Formulation	15 Oct, 2024	Granted	17 Oct, 2036
{"application_id":"34355","ingredient":"UPADACITINIB","trade_name":"RINVOQ","family_id":"c377044a6f994b4a802a","publication_number":"US10344036B2","cleaned_patent_number":"10344036","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2036-10-17","publication_date":"2019-07-09","legal_status":"Granted"}	US10344036B2 Formulation	09 Jul, 2019	Granted	17 Oct, 2036
{"application_id":"34351","ingredient":"UPADACITINIB","trade_name":"RINVOQ","family_id":"c377044a6f994b4a802a","publication_number":"US9951080B2","cleaned_patent_number":"9951080","drug_product_flag":"-, Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2036-10-17","publication_date":"2018-04-24","legal_status":"Granted"}	US9951080B2 Molecular	24 Apr, 2018	Granted	17 Oct, 2036
{"application_id":"34177","ingredient":"UPADACITINIB","trade_name":"RINVOQ","family_id":"c377044a6f994b4a802a","publication_number":"US9963459B2","cleaned_patent_number":"9963459","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2036-10-17","publication_date":"2018-05-08","legal_status":"Granted"}	US9963459B2 Formulation	08 May, 2018	Granted	17 Oct, 2036
{"application_id":"42504","ingredient":"UPADACITINIB","trade_name":"RINVOQ","family_id":"6696dbefd47b41e282ca","publication_number":"US11607411B2","cleaned_patent_number":"11607411","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2038-03-09","publication_date":"2023-03-21","legal_status":"Patented case"}	US11607411B2	21 Mar, 2023	Patented case	09 Mar, 2038
{"application_id":"105105","ingredient":"UPADACITINIB","trade_name":"RINVOQ","family_id":"6696dbefd47b41e282ca","publication_number":"US11564922B2","cleaned_patent_number":"11564922","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2038-03-09","publication_date":"2023-01-31","legal_status":"Granted"}	US11564922B2	31 Jan, 2023	Granted	09 Mar, 2038

Recent Clinical Trials

Latest clinical trials and research studies for this ingredient

NCT ID	Title	Status	Phase	Conditions	Start Date	Completion Date

API Suppliers/Manufacturer (Branded/Generic companies)

Manufacturing Locations

Filter by Country

View Complete Supplier List

Unlock access to all suppliers of Upadacitinib

✓ Access a comprehensive list of global suppliers

✓ Get information on each supplier

Unlock Suppliers

Note: Patent expirations and exclusivity timelines are dynamic and may shift based on litigation, regulatory extensions, and maintenance filings. Regular monitoring is advised.